Go Pro
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel Free CLPT Stock Alerts

ClearPoint Neuro (CLPT) Financials

ClearPoint Neuro logo
$17.29 -0.19 (-1.09%)
Closing price 07/8/2026 04:00 PM Eastern
Extended Trading
$17.31 +0.02 (+0.12%)
As of 07/8/2026 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for ClearPoint Neuro

Annual Income Statements for ClearPoint Neuro

This table shows ClearPoint Neuro's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -8.45 -8.07 -7.17 -6.16 -5.54 -6.78 -14 -16 -22 -19 -26
Consolidated Net Income / (Loss)		 -8.45 -8.07 -7.17 -6.16 -5.54 -6.78 -14 -16 -22 -19 -26
Net Income / (Loss) Continuing Operations		 -8.45 -8.07 -7.17 -6.16 -5.54 -6.78 -14 -16 -22 -19 -26
Total Pre-Tax Income 		-8.45 -8.07 -7.17 -6.16 -5.54 -6.78 -14 -16 -22 -19 -25
Total Operating Income		 -8.97 -7.49 -6.34 -5.25 -4.59 -6.22 -13 -16 -22 -20 -24
Total Gross Profit		 2.61 3.11 4.48 4.92 7.28 9.12 11 14 14 19 23
Total Revenue		 4.59 5.75 7.38 7.35 11 13 16 21 24 31 37
Operating Revenue		 4.59 5.75 7.38 7.35 11 13 16 21 24 31 37
Total Cost of Revenue		 1.99 2.64 2.90 2.43 3.94 3.71 5.18 7.02 10 12 14
Operating Cost of Revenue		 1.99 2.64 2.90 2.43 3.94 3.71 5.18 7.02 10 12 14
Total Operating Expenses		 12 11 11 10 12 15 24 30 36 39 47
Selling, General & Admin Expense		 8.37 4.19 4.05 4.33 4.30 5.27 8.00 9.61 12 12 16
Marketing Expense		 - 3.78 3.96 3.53 4.76 5.38 7.22 9.36 13 14 16
Research & Development Expense		 1.96 2.63 2.81 2.31 2.81 4.69 9.28 11 12 12 14
Total Other Income / (Expense), net		 0.52 -0.58 -0.83 -0.92 -0.95 -0.56 -1.04 -0.10 0.39 0.83 -1.32
Interest Expense		 1.26 1.86 0.87 0.98 0.96 1.44 0.97 0.08 -0.39 0.52 2.39
Interest & Investment Income		 0.02 - - - - - - - - 1.39 1.21
Other Income / (Expense), net		 1.77 1.28 0.04 0.06 0.01 0.88 -0.06 -0.02 - -0.04 -0.15
Income Tax Expense		 - - - - - - - - - 0.01 0.06
Basic Earnings per Share		 ($4.48) ($2.93) ($0.93) ($0.56) ($0.42) ($0.43) ($0.69) ($0.68) ($0.90) ($0.70) ($0.90)
Weighted Average Basic Shares Outstanding		 1.88M 2.75M 7.74M 10.93M 13.16M 15.85M 20.73M 24.18M 24.61M 27.03M 28.32M
Diluted Earnings per Share		 ($4.48) ($2.93) ($0.93) ($0.56) ($0.42) ($0.43) ($0.69) ($0.68) ($0.90) ($0.70) ($0.90)
Weighted Average Diluted Shares Outstanding		 1.88M 2.75M 7.74M 10.93M 13.16M 15.85M 20.73M 24.18M 24.61M 27.03M 28.32M
Weighted Average Basic & Diluted Shares Outstanding		 1.88M 2.75M 7.74M 10.93M 13.16M 15.85M 20.73M 24.61M 26.98M 27.63M 29.66M

Quarterly Income Statements for ClearPoint Neuro

This table shows ClearPoint Neuro's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.81 -4.62 -4.15 -4.41 -4.97 -5.39 -6.03 -5.84 -5.89 -7.79 -9.55
Consolidated Net Income / (Loss)		 -4.81 -4.62 -4.15 -4.41 -4.97 -5.39 -6.03 -5.84 -5.89 -7.79 -9.55
Net Income / (Loss) Continuing Operations		 -4.81 -4.62 -4.15 -4.41 -4.97 -5.39 -6.03 -5.84 -5.89 -7.79 -9.55
Total Pre-Tax Income 		-4.80 -4.60 -4.13 -4.39 -4.96 -5.39 -6.01 -5.81 -5.88 -7.78 -9.54
Total Operating Income		 -4.90 -4.71 -4.22 -4.72 -5.16 -5.60 -6.16 -5.68 -5.28 -7.05 -8.48
Total Gross Profit		 3.27 4.01 4.53 4.99 4.85 4.76 5.13 5.56 5.60 6.40 7.76
Total Revenue		 5.76 6.81 7.64 7.86 8.12 7.77 8.49 9.22 8.86 10 12
Operating Revenue		 5.76 6.81 7.64 7.86 8.12 7.77 8.49 9.22 8.86 10 12
Total Cost of Revenue		 2.49 2.80 3.11 2.87 3.28 3.01 3.35 3.66 3.26 4.01 4.37
Operating Cost of Revenue		 2.49 2.80 3.11 2.87 3.28 3.01 3.35 3.66 3.26 4.01 4.37
Total Operating Expenses		 8.17 8.72 8.74 9.71 10 10 11 11 11 13 16
Selling, General & Admin Expense		 2.90 2.72 2.83 2.76 3.14 3.23 4.08 3.39 3.59 5.44 5.00
Marketing Expense		 2.84 3.35 3.29 3.83 3.55 3.81 3.83 4.02 3.84 4.77 6.72
Research & Development Expense		 2.43 2.65 2.63 3.12 3.32 3.33 3.38 3.83 3.45 3.24 4.52
Total Other Income / (Expense), net		 0.10 0.10 0.09 0.33 0.20 0.22 0.16 -0.13 -0.61 -0.74 -1.07
Interest Expense		 -0.10 -0.09 -0.11 -0.33 -0.21 -0.23 0.00 0.08 0.54 1.92 1.38
Interest & Investment Income		 - - - - - - 0.15 - - - 0.35
Other Income / (Expense), net		 - - -0.03 0.01 -0.01 -0.01 0.00 -0.05 -0.06 -0.03 -0.04
Income Tax Expense		 - - 0.02 0.02 0.01 - 0.02 0.03 0.01 0.00 0.01
Basic Earnings per Share		 ($0.20) ($0.18) ($0.16) ($0.16) ($0.18) ($0.20) ($0.22) ($0.21) ($0.21) ($0.26) ($0.32)
Weighted Average Basic Shares Outstanding		 24.63M 24.61M 25.45M 27.47M 27.59M 27.03M 27.72M 28.26M 28.43M 28.32M 29.55M
Diluted Earnings per Share		 ($0.20) ($0.18) ($0.16) ($0.16) ($0.18) ($0.20) ($0.22) ($0.21) ($0.21) ($0.26) ($0.32)
Weighted Average Diluted Shares Outstanding		 24.63M 24.61M 25.45M 27.47M 27.59M 27.03M 27.72M 28.26M 28.43M 28.32M 29.55M
Weighted Average Basic & Diluted Shares Outstanding		 24.62M 26.98M 27.42M 27.60M 27.58M 27.63M 27.99M 28.43M 28.42M 29.66M 29.99M

Annual Cash Flow Statements for ClearPoint Neuro

This table details how cash moves in and out of ClearPoint Neuro's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -3.84 -2.09 5.97 -6.19 2.60 14 34 -26 -4.48 -3.04 27
Net Cash From Operating Activities		 -8.64 -5.82 -5.99 -4.63 -2.85 -7.81 -13 -16 -14 -8.95 -24
Net Cash From Continuing Operating Activities		 -8.64 -5.82 -5.99 -4.63 -2.85 -7.81 -13 -16 -14 -8.95 -24
Net Income / (Loss) Continuing Operations		 -8.45 -8.07 -7.17 -6.16 -5.54 -6.78 -14 -16 -22 -19 -26
Consolidated Net Income / (Loss)		 -8.45 -8.07 -7.17 -6.16 -5.54 -6.78 -14 -16 -22 -19 -26
Depreciation Expense		 0.21 0.16 0.12 0.11 0.14 0.33 0.16 0.24 0.63 0.98 0.81
Amortization Expense		 0.47 0.42 0.43 0.56 0.84 1.11 0.63 0.30 0.76 0.97 1.51
Non-Cash Adjustments To Reconcile Net Income		 0.29 1.00 1.72 1.24 0.69 0.22 2.61 3.47 6.58 6.61 9.11
Changes in Operating Assets and Liabilities, net		 -1.16 0.67 -1.09 -0.38 1.02 -2.69 -1.68 -3.75 0.40 1.40 -9.81
Net Cash From Investing Activities		 -0.08 -0.10 -0.03 -0.06 -0.16 -0.48 -0.17 -11 8.95 -0.28 0.62
Net Cash From Continuing Investing Activities		 -0.08 -0.10 -0.03 -0.06 -0.16 -0.48 -0.17 -11 8.95 -0.28 0.62
Purchase of Property, Plant & Equipment		 -0.08 -0.10 -0.03 -0.06 -0.01 -0.04 -0.17 -0.25 -0.72 -0.28 -0.52
Divestitures		 - - - - - - - - - 0.00 1.14
Other Investing Activities, net		 - - - - - -0.44 - - - 0.00 0.00
Net Cash From Financing Activities		 4.88 3.83 12 -1.49 5.61 23 47 0.41 0.30 6.19 50
Net Cash From Continuing Financing Activities		 4.88 3.83 12 -1.49 5.61 23 47 0.41 0.30 6.19 50
Repayment of Debt		 - - 0.00 -2.00 -2.21 -2.84 - - 0.00 -10 0.00
Issuance of Debt		 - - - - 0.00 25 - - - 0.00 48
Issuance of Common Equity		 - - 12 0.00 7.82 0.00 47 0.48 0.51 17 3.82
Other Financing Activities, net		 4.88 3.83 0.00 0.51 - 0.38 -0.13 -0.07 -0.21 -0.40 -1.73
Cash Interest Paid		 0.22 0.98 0.35 0.21 0.32 1.58 0.60 0.52 0.74 0.48 0.91
Cash Income Taxes Paid		 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.06 0.07

Quarterly Cash Flow Statements for ClearPoint Neuro

This table details how cash moves in and out of ClearPoint Neuro's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -2.12 -1.20 12 -2.51 -11 -1.47 -7.72 29 -3.32 8.57 -10
Net Cash From Operating Activities		 -1.80 -1.17 -3.84 -2.67 -1.20 -1.24 -6.17 -2.55 -3.12 -12 -7.97
Net Cash From Continuing Operating Activities		 -1.80 -1.17 -3.84 -2.67 -1.20 -1.24 -6.17 -2.55 -3.12 -12 -7.97
Net Income / (Loss) Continuing Operations		 -4.81 -4.62 -4.15 -4.41 -4.97 -5.39 -6.03 -5.84 -5.89 -7.79 -9.55
Consolidated Net Income / (Loss)		 -4.81 -4.62 -4.15 -4.41 -4.97 -5.39 -6.03 -5.84 -5.89 -7.79 -9.55
Depreciation Expense		 0.16 0.18 0.24 0.69 -0.20 0.24 0.10 0.40 0.07 0.25 0.09
Amortization Expense		 0.28 0.26 0.25 -0.22 0.71 0.23 0.23 0.25 0.40 0.63 1.07
Non-Cash Adjustments To Reconcile Net Income		 2.03 1.14 1.19 1.44 1.90 1.91 2.13 2.44 2.34 2.20 2.65
Changes in Operating Assets and Liabilities, net		 0.54 1.87 -1.37 -0.17 1.35 1.76 -2.61 0.20 -0.04 -7.37 -2.22
Net Cash From Investing Activities		 -0.24 -0.19 0.00 - -0.01 -0.26 -0.18 -0.09 -0.20 1.09 -0.65
Net Cash From Continuing Investing Activities		 -0.24 -0.19 0.00 - -0.01 -0.26 -0.18 -0.09 -0.20 1.09 -0.65
Purchase of Property, Plant & Equipment		 -0.24 -0.02 0.00 - -0.01 -0.26 -0.18 -0.09 -0.20 -0.05 -0.65
Other Investing Activities, net		 - - - - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 -0.09 0.16 16 0.16 -10 0.04 -1.36 32 - 20 -1.85
Net Cash From Continuing Financing Activities		 -0.09 0.16 16 0.16 -10 0.04 -1.36 32 - 20 -1.85
Other Financing Activities, net		 -0.09 -0.04 -0.13 -0.13 -0.06 -0.08 -1.36 -0.25 - -0.12 -1.85
Cash Interest Paid		 0.19 0.19 0.19 0.19 0.11 - 0.00 0.17 0.32 0.42 0.53
Cash Income Taxes Paid		 - - 0.00 - - 0.06 0.00 0.01 0.06 - 0.00

Annual Balance Sheets for ClearPoint Neuro

This table presents ClearPoint Neuro's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 9.94 7.40 14 7.86 12 30 66 55 43 39 98
Total Current Assets		 8.53 6.09 13 6.65 10 25 62 51 36 33 64
Cash & Equivalents		 5.41 3.32 9.29 3.10 5.70 20 54 28 23 20 46
Accounts Receivable		 1.22 0.87 0.95 1.23 1.09 1.88 2.34 2.67 3.21 4.71 6.55
Inventories, net		 1.81 1.77 2.31 2.11 3.24 3.24 4.94 9.30 7.91 6.86 8.36
Prepaid Expenses		 0.10 0.13 0.19 0.21 0.36 0.24 0.51 1.72 1.91 1.68 2.77
Plant, Property, & Equipment, net		 0.44 0.33 0.27 0.38 0.45 0.32 0.54 0.81 1.39 2.01 2.62
Total Noncurrent Assets		 0.96 0.99 0.88 0.82 1.10 3.74 3.15 3.50 5.10 3.82 32
Goodwill		 - - - - - - - - - 0.00 7.47
Intangible Assets		 - - - - - - - - 1.04 0.00 14
Other Noncurrent Operating Assets		 0.96 0.99 0.88 0.82 1.10 3.74 3.15 3.50 4.06 3.82 10
Total Liabilities & Shareholders' Equity		 9.94 7.40 14 7.86 12 30 66 55 43 39 98
Total Liabilities		 12 8.16 8.07 6.35 7.34 27 17 19 21 14 70
Total Current Liabilities		 7.65 3.02 4.40 1.87 3.83 3.20 4.75 6.79 7.43 10 11
Accounts Payable		 0.70 1.55 0.76 0.50 0.97 0.30 0.43 0.27 0.39 1.34 1.26
Accrued Expenses		 1.40 0.45 0.48 0.39 0.33 0.35 0.54 2.07 1.05 1.45 2.79
Current Deferred Revenue		 0.12 0.22 0.26 0.21 1.02 0.56 0.68 1.07 2.61 2.12 1.67
Current Employee Benefit Liabilities		 0.56 0.67 0.81 0.76 1.41 1.60 2.60 2.82 2.95 4.89 4.36
Other Current Liabilities		 0.66 0.13 0.10 0.00 0.11 0.39 0.51 0.56 0.42 0.56 0.69
Total Noncurrent Liabilities		 0.54 5.14 3.67 4.48 3.51 24 12 12 14 3.45 59
Long-Term Debt		 0.00 4.49 2.92 3.48 2.07 21 9.84 9.89 9.95 0.00 49
Noncurrent Deferred Revenue		 - - - 0.14 0.20 0.22 0.26 0.39 0.54 0.44 0.58
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - - 0.00 0.35
Other Noncurrent Operating Liabilities		 0.54 0.65 0.75 0.86 1.24 2.45 1.94 1.53 3.57 3.01 8.95
Commitments & Contingencies		 - 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -1.98 -0.76 5.83 1.51 4.59 2.38 49 37 21 25 28
Total Preferred & Common Equity		 -1.98 -0.76 5.83 1.51 4.59 2.38 49 37 21 25 28
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -1.98 -0.76 5.83 1.51 4.59 2.38 49 37 21 25 28
Common Stock		 84 93 107 109 117 122 183 187 194 217 245
Retained Earnings		 -86 -94 -101 -107 -113 -120 -134 -150 -172 -191 -217

Quarterly Balance Sheets for ClearPoint Neuro

This table presents ClearPoint Neuro's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 58 50 48 44 54 53 40 30 63 60 93
Total Current Assets		 54 46 41 37 48 47 34 24 54 51 55
Cash & Equivalents		 19 22 26 24 35 33 22 12 42 38 36
Accounts Receivable		 3.41 2.68 2.80 2.42 2.51 3.48 3.88 3.65 4.26 4.00 8.66
Inventories, net		 8.28 9.81 9.20 8.99 7.96 8.03 7.06 6.58 6.29 6.58 8.57
Prepaid Expenses		 1.66 1.76 2.24 1.56 1.75 2.21 1.82 1.59 1.90 2.53 2.05
Plant, Property, & Equipment, net		 0.63 0.95 1.36 1.36 1.35 1.55 1.70 2.18 2.02 2.11 2.91
Total Noncurrent Assets		 3.30 3.31 5.57 5.17 4.72 4.47 4.17 3.67 6.86 6.91 36
Goodwill		 - - - - - - - - - - 7.47
Intangible Assets		 - - - 0.97 0.89 0.76 0.61 0.46 - - 13
Other Noncurrent Operating Assets		 3.30 3.31 5.57 4.20 3.83 3.72 3.56 3.22 6.86 6.91 15
Total Liabilities & Shareholders' Equity		 58 50 48 44 54 53 40 30 63 60 93
Total Liabilities		 18 18 20 20 19 20 11 10 43 44 75
Total Current Liabilities		 6.10 6.05 6.20 5.59 15 17 7.55 6.87 7.40 8.05 9.48
Accounts Payable		 1.39 1.35 1.27 0.79 0.84 0.82 0.96 1.22 1.53 0.72 2.33
Accrued Expenses		 1.25 1.40 1.37 0.95 0.99 1.30 1.18 1.51 1.21 1.75 2.13
Current Deferred Revenue		 0.74 1.28 0.72 1.18 1.23 1.08 1.25 1.62 0.00 1.72 1.81
Current Employee Benefit Liabilities		 2.19 1.45 2.34 2.29 1.63 3.00 3.64 1.94 2.95 3.52 2.98
Other Current Liabilities		 0.54 0.57 0.49 0.38 0.50 0.52 0.54 0.58 1.71 0.35 0.23
Total Noncurrent Liabilities		 12 12 14 14 3.90 3.75 3.64 3.22 36 36 65
Long-Term Debt		 9.88 9.91 9.92 9.94 0.00 0.00 0.00 0.00 29 29 50
Noncurrent Deferred Revenue		 0.35 0.32 0.25 0.52 0.46 0.45 0.48 0.36 0.00 0.77 0.61
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - - - 0.35
Other Noncurrent Operating Liabilities		 1.54 1.39 3.86 3.70 3.44 3.30 3.16 2.86 6.88 6.46 14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 40 33 27 24 35 32 29 20 20 16 19
Total Preferred & Common Equity		 40 33 27 24 35 32 29 20 20 16 19
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 40 33 27 24 35 32 29 20 20 16 19
Common Stock		 186 189 190 192 211 213 215 217 223 225 245
Retained Earnings		 -146 -156 -163 -168 -177 -181 -186 -197 -203 -209 -226

Annual Metrics And Ratios for ClearPoint Neuro

This table displays calculated financial ratios and metrics derived from ClearPoint Neuro's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 74,971,026.00 3,610,524.00 10,401,115.00 11,022,372.00 15,205,867.00 16,869,528.00 23,639,616.00 - - - 28,423,308.00
DEI Adjusted Shares Outstanding		 74,971,026.00 3,610,524.00 10,401,115.00 11,022,372.00 15,205,867.00 16,869,528.00 23,639,616.00 - - - 28,423,308.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.11 -2.24 -0.69 -0.56 -0.36 -0.40 -0.61 - - - -0.90
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 27.46% 25.15% 28.35% -0.36% 52.54% 14.37% 27.05% 26.09% 16.56% 31.04% 17.78%
EBITDA Growth		 -125.84% 13.71% -2.22% 21.56% 20.09% -8.13% -224.40% -25.00% -33.23% 15.32% -23.40%
EBIT Growth		 -100.35% 13.84% -1.41% 17.65% 11.55% -16.42% -151.72% -21.71% -37.25% 11.85% -22.94%
NOPAT Growth		 -68.67% 16.55% 15.40% 17.17% 12.46% -35.39% -115.02% -22.12% -37.44% 12.03% -22.45%
Net Income Growth		 -86.73% 4.49% 11.18% 14.01% 10.12% -22.42% -112.47% -14.05% -34.40% 14.37% -35.03%
EPS Growth		 -5,500.00% 34.60% 68.26% 39.78% 25.00% -2.38% -60.47% 1.45% -32.35% 22.22% -28.57%
Operating Cash Flow Growth		 -19.14% 32.62% -2.96% 22.73% 38.45% -173.93% -62.64% -27.33% 15.14% 34.77% -167.32%
Free Cash Flow Firm Growth		 -112.43% 39.89% -7.19% 24.95% 44.28% -203.68% -48.51% -57.05% 11.13% 22.76% -285.04%
Invested Capital Growth		 133.69% -24.63% 246.98% 29.75% -49.06% 269.47% 26.93% 105.74% -14.09% -33.79% 489.86%
Revenue Q/Q Growth		 13.65% 2.20% 0.60% 8.84% 9.08% 4.10% 3.60% 4.54% 7.33% 3.16% 7.69%
EBITDA Q/Q Growth		 11.33% -12.99% -6.76% 16.61% -10.57% 2.61% -27.68% -4.45% 0.75% -5.35% -4.86%
EBIT Q/Q Growth		 10.28% -10.55% -6.43% 14.31% -10.53% 0.73% -24.08% -3.21% -1.07% -4.98% -6.22%
NOPAT Q/Q Growth		 12.30% -5.21% -0.67% 14.00% -10.58% -15.74% -14.74% -3.07% -1.07% -4.76% -6.14%
Net Income Q/Q Growth		 7.82% -6.36% -5.92% 12.29% -8.37% 0.93% -21.68% -1.46% -1.07% -4.23% -10.37%
EPS Q/Q Growth		 -134.56% 45.44% 18.42% -21.74% 2.33% 99.52% -100.77% 4.23% 0.00% -2.94% -7.14%
Operating Cash Flow Q/Q Growth		 7.26% 3.41% -11.83% 20.08% 3.91% -32.95% -9.97% 2.92% 12.14% -0.83% -82.80%
Free Cash Flow Firm Q/Q Growth		 12.46% 1.70% -11.27% 23.03% -300.21% 3.71% -14.50% 0.60% 9.63% -1.74% -178.58%
Invested Capital Q/Q Growth		 72.88% -21.14% 39.44% -10.36% 523.83% 10.23% 10.63% -0.05% -17.60% -28.85% 354.70%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 56.74% 54.03% 60.72% 66.91% 64.86% 71.09% 68.24% 65.84% 56.83% 60.92% 61.38%
EBITDA Margin		 -141.92% -97.86% -77.94% -61.35% -32.14% -30.38% -77.58% -76.91% -87.91% -56.81% -59.48%
Operating Margin		 -195.34% -130.25% -85.86% -71.37% -40.96% -48.48% -82.05% -79.47% -93.70% -62.91% -65.36%
EBIT Margin		 -156.79% -107.95% -85.30% -70.49% -40.88% -41.61% -82.44% -79.58% -93.70% -63.03% -65.75%
Profit (Net Income) Margin		 -183.91% -140.36% -97.12% -83.82% -49.39% -52.86% -88.41% -79.97% -92.21% -60.25% -69.08%
Tax Burden Percent		 100.00% 100.00% 100.00% 99.99% 100.00% 100.00% 100.00% 100.00% 100.13% 100.00% 100.22%
Interest Burden Percent		 117.30% 130.02% 113.87% 118.91% 120.83% 127.05% 107.24% 100.50% 98.28% 95.59% 104.83%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -1,073.09% -472.59% -219.47% -225.39% -192.61% -231.90% -165.60% -181.93% -208.37% -92.79%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -1,225.35% -301.59% -94.73% -82.08% 6.24% -208.47% -151.68% -150.66% -177.78% 8.98%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 1,662.73% 190.00% 51.52% 43.66% -2.19% 175.57% 127.24% 105.84% 127.13% -2.85%
Return on Equity (ROE)		 811.85% 589.64% -282.59% -167.95% -181.73% -194.80% -56.33% -38.37% -76.09% -81.24% -95.64%
Cash Return on Invested Capital (CROIC)		 -1,524.42% -1,045.00% -583.10% -245.37% -160.38% -307.41% -255.63% -234.77% -166.77% -167.71% -234.81%
Operating Return on Assets (OROA)		 -61.77% -71.60% -59.11% -47.65% -46.35% -25.76% -28.26% -27.02% -45.74% -48.35% -35.51%
Return on Assets (ROA)		 -72.46% -93.09% -67.30% -56.66% -56.01% -32.73% -30.31% -27.15% -45.01% -46.22% -37.30%
Return on Common Equity (ROCE)		 811.85% 589.64% -282.59% -167.95% -181.73% -194.80% -56.33% -38.37% -76.09% -81.24% -95.64%
Return on Equity Simple (ROE_SIMPLE)		 426.48% 1,067.35% -122.97% -407.91% -120.80% -285.32% -29.54% -44.56% -104.33% -74.50% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.28 -5.24 -4.44 -3.67 -3.22 -4.35 -9.36 -11 -16 -14 -17
NOPAT Margin		 -136.74% -91.18% -60.10% -49.96% -28.67% -33.94% -57.44% -55.63% -65.59% -44.03% -45.75%
Net Nonoperating Expense Percent (NNEP)		 440.12% 152.27% -170.99% -124.74% -143.31% -198.85% -23.43% -13.92% -31.27% -30.59% -101.77%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -50.49% -54.44% -21.94%
Cost of Revenue to Revenue		 43.26% 45.97% 39.28% 33.09% 35.14% 28.91% 31.76% 34.16% 43.17% 39.08% 38.62%
SG&A Expenses to Revenue		 182.20% 72.88% 54.83% 58.83% 38.36% 41.08% 49.08% 46.77% 49.08% 38.22% 44.62%
R&D to Revenue		 42.60% 45.71% 38.13% 31.42% 25.05% 36.53% 56.94% 53.01% 48.88% 39.48% 37.59%
Operating Expenses to Revenue		 252.07% 184.29% 146.58% 138.28% 105.81% 119.57% 150.30% 145.31% 150.53% 123.82% 126.74%
Earnings before Interest and Taxes (EBIT)		 -7.20 -6.21 -6.29 -5.18 -4.59 -5.34 -13 -16 -22 -20 -24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.52 -5.63 -5.75 -4.51 -3.61 -3.90 -13 -16 -21 -18 -22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 2.05 13.57 15.92 112.77 5.44 5.64 7.90 16.71 13.88
Price to Tangible Book Value (P/TBV)		 0.00 0.00 2.05 13.57 15.92 112.77 5.44 5.64 8.30 17.03 58.68
Price to Revenue (P/Rev)		 18.77 0.72 1.62 2.79 6.51 20.89 16.27 10.12 6.98 13.52 10.52
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 152.63 12.69 5.21 11.05 72.03 75.67 48.93 19.41 19.29 76.47 12.57
Enterprise Value to Revenue (EV/Rev)		 18.51 0.93 1.03 2.84 6.18 20.99 13.56 8.78 6.43 12.88 10.60
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -2.13 -5.94 0.84 2.30 0.45 8.95 0.20 0.27 0.47 0.00 1.75
Long-Term Debt to Equity		 0.00 -5.94 0.50 2.30 0.45 8.95 0.20 0.27 0.47 0.00 1.75
Financial Leverage		 -0.47 -1.36 -0.63 -0.54 -0.53 -0.35 -0.84 -0.84 -0.70 -0.72 -0.32
Leverage Ratio		 -11.20 -6.33 4.20 2.96 3.24 5.95 1.86 1.41 1.69 1.76 2.56
Compound Leverage Factor		 -13.14 -8.24 4.78 3.52 3.92 7.56 1.99 1.42 1.66 1.68 2.69
Debt to Total Capital		 188.31% 120.24% 45.76% 69.73% 31.13% 89.95% 16.78% 21.15% 31.97% 0.00% 63.66%
Short-Term Debt to Total Capital		 188.31% 0.00% 18.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 120.24% 27.15% 69.73% 31.13% 89.95% 16.78% 21.15% 31.97% 0.00% 63.66%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -88.31% -20.24% 54.24% 30.27% 68.87% 10.05% 83.22% 78.85% 68.03% 100.00% 36.34%
Debt to EBITDA		 -0.65 -0.80 -0.86 -0.77 -0.58 -5.46 -0.78 -0.63 -0.47 0.00 -2.23
Net Debt to EBITDA		 0.18 -0.21 0.76 -0.08 1.01 -0.30 3.50 1.75 0.63 0.00 -0.14
Long-Term Debt to EBITDA		 0.00 -0.80 -0.51 -0.77 -0.58 -5.46 -0.78 -0.63 -0.47 0.00 -2.23
Debt to NOPAT		 -0.67 -0.86 -1.11 -0.95 -0.64 -4.89 -1.05 -0.87 -0.63 0.00 -2.90
Net Debt to NOPAT		 0.19 -0.22 0.99 -0.10 1.13 -0.27 4.73 2.41 0.84 0.00 -0.19
Long-Term Debt to NOPAT		 0.00 -0.86 -0.66 -0.95 -0.64 -4.89 -1.05 -0.87 -0.63 0.00 -2.90
Altman Z-Score		 -9.56 -18.94 -9.53 -17.67 -6.94 1.00 7.23 3.27 -1.36 11.45 0.45
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.11 2.02 2.90 3.56 2.71 7.96 13.02 7.54 4.87 3.22 5.91
Quick Ratio		 0.87 1.39 2.33 2.32 1.77 6.87 11.88 5.92 3.55 2.40 4.87
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -8.49 -5.10 -5.47 -4.11 -2.29 -6.95 -10 -16 -14 -11 -43
Operating Cash Flow to CapEx		 -11,234.91% -5,762.30% -22,400.24% -7,293.42% -28,500.00% -19,041.46% -7,557.74% -6,390.12% -1,913.53% -3,254.55% -4,583.33%
Free Cash Flow to Firm to Interest Expense		 -6.73 -2.74 -6.27 -4.19 -2.40 -4.81 -10.61 -200.09 0.00 0.00 -17.92
Operating Cash Flow to Interest Expense		 -6.84 -3.12 -6.86 -4.72 -2.98 -5.41 -13.05 -199.59 0.00 0.00 -10.02
Operating Cash Flow Less CapEx to Interest Expense		 -6.90 -3.18 -6.90 -4.79 -2.99 -5.43 -13.22 -202.72 0.00 0.00 -10.24
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.39 0.66 0.69 0.68 1.13 0.62 0.34 0.34 0.49 0.77 0.54
Accounts Receivable Turnover		 5.45 5.52 8.13 6.74 9.65 8.64 7.73 8.22 8.15 7.92 6.57
Inventory Turnover		 1.05 1.48 1.42 1.10 1.47 1.15 1.27 0.99 1.20 1.66 1.88
Fixed Asset Turnover		 9.95 14.96 24.77 22.79 27.20 33.50 37.99 30.56 21.83 18.50 15.98
Accounts Payable Turnover		 2.35 2.35 2.51 3.86 5.37 5.86 14.24 20.09 31.10 14.16 11.00
Days Sales Outstanding (DSO)		 67.01 66.15 44.89 54.19 37.81 42.26 47.23 44.42 44.77 46.07 55.59
Days Inventory Outstanding (DIO)		 346.42 246.97 257.03 331.55 247.50 318.75 288.28 370.23 303.80 219.78 194.55
Days Payable Outstanding (DPO)		 155.62 155.01 145.20 94.54 67.91 62.29 25.63 18.17 11.74 25.78 33.18
Cash Conversion Cycle (CCC)		 257.81 158.10 156.72 291.20 217.40 298.72 309.87 396.47 336.83 240.07 216.97
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.56 0.42 1.46 1.89 0.96 3.56 4.52 9.29 7.98 5.29 31
Invested Capital Turnover		 -8.38 11.77 7.86 4.39 7.86 5.68 4.04 2.98 2.77 4.73 2.03
Increase / (Decrease) in Invested Capital		 2.21 -0.14 1.04 0.43 -0.93 2.60 0.96 4.78 -1.31 -2.70 26
Enterprise Value (EV)		 85 5.33 7.59 21 69 269 221 180 154 404 392
Market Capitalization		 86 4.15 12 21 73 268 265 208 167 424 389
Book Value per Share		 ($0.03) ($0.21) $0.56 $0.14 $0.30 $0.14 $2.06 $1.50 $0.86 $0.92 $0.99
Tangible Book Value per Share		 ($0.03) ($0.21) $0.56 $0.14 $0.30 $0.14 $2.06 $1.50 $0.82 $0.90 $0.23
Total Capital		 2.24 3.74 11 4.99 6.66 24 59 47 31 25 77
Total Debt		 4.22 4.49 4.92 3.48 2.07 21 9.84 9.89 9.95 0.00 49
Total Long-Term Debt		 0.00 4.49 2.92 3.48 2.07 21 9.84 9.89 9.95 0.00 49
Net Debt		 -1.18 1.18 -4.37 0.38 -3.62 1.18 -44 -28 -13 -20 3.15
Capital Expenditures (CapEx)		 0.08 0.10 0.03 0.06 0.01 0.04 0.17 0.25 0.72 0.28 0.52
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.31 -0.25 1.06 1.69 0.86 2.16 3.03 6.90 5.60 2.91 6.91
Debt-free Net Working Capital (DFNWC)		 5.10 3.07 10 4.79 6.55 22 57 44 29 23 53
Net Working Capital (NWC)		 0.88 3.07 8.35 4.79 6.55 22 57 44 29 23 53
Net Nonoperating Expense (NNE)		 2.17 2.83 2.73 2.49 2.32 2.43 5.05 5.00 6.38 5.09 8.63
Net Nonoperating Obligations (NNO)		 2.54 1.18 -4.37 0.38 -3.62 1.18 -44 -28 -13 -20 3.15
Total Depreciation and Amortization (D&A)		 0.68 0.58 0.54 0.67 0.98 1.44 0.79 0.55 1.39 1.95 2.32
Debt-free, Cash-free Net Working Capital to Revenue		 -6.65% -4.32% 14.34% 22.93% 7.62% 16.86% 18.59% 33.59% 23.39% 9.26% 18.70%
Debt-free Net Working Capital to Revenue		 111.08% 53.35% 140.23% 65.10% 58.40% 173.53% 350.57% 216.01% 119.98% 73.30% 142.91%
Net Working Capital to Revenue		 19.12% 53.35% 113.13% 65.10% 58.40% 173.53% 350.57% 216.01% 119.98% 73.30% 142.91%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.11) ($2.93) ($0.93) ($0.56) ($0.42) ($0.43) ($0.69) ($0.68) ($0.90) ($0.70) ($0.90)
Adjusted Weighted Average Basic Shares Outstanding		 91.65M 3.62M 10.69M 11.05M 15.49M 20.67M 23.69M 24.18M 24.61M 27.03M 28.32M
Adjusted Diluted Earnings per Share		 ($0.11) ($2.93) ($0.93) ($0.56) ($0.42) ($0.43) ($0.69) ($0.68) ($0.90) ($0.70) ($0.90)
Adjusted Weighted Average Diluted Shares Outstanding		 91.65M 3.62M 10.69M 11.05M 15.49M 20.67M 23.69M 24.18M 24.61M 27.03M 28.32M
Adjusted Basic & Diluted Earnings per Share		 ($0.11) ($2.93) ($0.93) ($0.56) ($0.42) ($0.43) ($0.69) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 75.39M 2.75M 7.74M 10.93M 13.16M 15.85M 20.73M 24.61M 26.98M 27.63M 29.66M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.41 -5.24 -4.44 -3.67 -3.22 -4.35 -9.36 -11 -16 -14 -17
Normalized NOPAT Margin		 -117.65% -91.18% -60.10% -49.96% -28.67% -33.94% -57.44% -55.63% -65.59% -44.03% -45.75%
Pre Tax Income Margin		 -183.91% -140.36% -97.12% -83.82% -49.39% -52.86% -88.41% -79.97% -92.09% -60.25% -68.93%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -5.71 -3.33 -7.21 -5.29 -4.80 -3.70 -13.81 -201.90 0.00 0.00 -10.18
NOPAT to Interest Expense		 -4.98 -2.81 -5.08 -3.75 -3.37 -3.02 -9.62 -141.14 0.00 0.00 -7.08
EBIT Less CapEx to Interest Expense		 -5.77 -3.39 -7.24 -5.35 -4.81 -3.73 -13.98 -205.02 0.00 0.00 -10.40
NOPAT Less CapEx to Interest Expense		 -5.04 -2.87 -5.11 -3.81 -3.38 -3.04 -9.79 -144.26 0.00 0.00 -7.30
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for ClearPoint Neuro

This table displays calculated financial ratios and metrics derived from ClearPoint Neuro's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 27,632,332.00 27,989,194.00 28,427,417.00 28,423,308.00 29,663,875.00
DEI Adjusted Shares Outstanding		 - - - - - - 27,632,332.00 27,989,194.00 28,427,417.00 28,423,308.00 29,663,875.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.22 -0.21 -0.21 -0.27 -0.32
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 11.97% 31.62% 40.60% 32.07% 40.96% 14.11% 11.07% 17.27% 9.10% 33.96% 42.93%
EBITDA Growth		 -18.24% 3.61% 31.58% 37.74% -4.62% -20.48% -55.21% -19.87% -4.79% -19.95% -26.32%
EBIT Growth		 -28.19% -5.30% 25.62% 33.63% -5.84% -19.25% -45.19% -21.47% -3.31% -25.43% -38.22%
NOPAT Growth		 -29.04% -5.30% 25.93% 33.54% -5.62% -19.08% -46.18% -20.24% -2.29% -25.00% -37.56%
Net Income Growth		 -26.95% -5.34% 26.08% 37.49% -3.43% -16.61% -45.34% -32.42% -18.44% -44.56% -58.51%
EPS Growth		 -33.33% 0.00% 30.43% 44.83% 10.00% -11.11% -37.50% -31.25% -16.67% -30.00% -45.45%
Operating Cash Flow Growth		 53.37% 61.86% 32.39% 47.43% 33.24% -6.33% -60.73% 4.35% -160.30% -871.84% -29.08%
Free Cash Flow Firm Growth		 51.48% 74.88% 84.09% 79.35% 64.35% 38.25% -95.03% -3.00% -130.93% -2,369.20% -1,048.42%
Invested Capital Growth		 4.21% -14.09% -14.48% -14.73% -23.32% -33.79% -17.35% -23.95% -7.70% 489.86% 332.79%
Revenue Q/Q Growth		 -3.16% 18.19% 12.17% 2.87% 3.36% -4.32% 9.19% 8.60% -3.84% 17.48% 16.50%
EBITDA Q/Q Growth		 34.77% 4.33% 11.78% -12.98% -9.61% -10.18% -12.60% 12.70% 4.13% -27.28% -18.58%
EBIT Q/Q Growth		 31.35% 3.90% 9.62% -11.21% -9.48% -8.28% -9.12% 6.93% 6.84% -32.57% -20.26%
NOPAT Q/Q Growth		 31.33% 3.90% 10.09% -12.01% -9.14% -8.35% -9.35% 7.84% 7.11% -33.53% -20.34%
Net Income Q/Q Growth		 31.81% 3.95% 10.24% -6.32% -12.84% -8.28% -11.88% 3.14% -0.93% -32.17% -22.68%
EPS Q/Q Growth		 31.03% 10.00% 11.11% 0.00% -12.50% -11.11% -10.00% 4.55% 0.00% -23.81% -23.08%
Operating Cash Flow Q/Q Growth		 64.61% 34.91% -228.49% 30.52% 55.06% -3.67% -396.54% 58.65% -22.30% -287.06% 34.05%
Free Cash Flow Firm Q/Q Growth		 54.05% 48.02% 29.24% -22.18% 20.68% 9.96% -117.84% 35.38% -77.64% -887.46% -1.32%
Invested Capital Q/Q Growth		 -10.86% -17.60% 15.20% 0.77% -19.84% -28.85% 43.80% -7.28% -2.71% 354.70% 5.51%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 56.80% 58.93% 59.24% 63.48% 59.68% 61.28% 60.48% 60.29% 63.20% 61.52% 63.95%
EBITDA Margin		 -77.40% -62.66% -49.33% -54.17% -57.45% -66.16% -68.65% -55.18% -55.02% -59.61% -60.67%
Operating Margin		 -84.99% -69.10% -55.39% -60.31% -63.68% -72.11% -72.63% -61.64% -59.54% -67.68% -69.90%
EBIT Margin		 -84.99% -69.10% -55.73% -60.24% -63.81% -72.22% -72.59% -62.20% -60.26% -68.00% -70.19%
Profit (Net Income) Margin		 -83.46% -67.83% -54.27% -56.10% -61.24% -69.31% -71.02% -63.34% -66.48% -74.79% -78.76%
Tax Burden Percent		 100.25% 100.37% 100.00% 100.00% 100.00% 100.00% 100.30% 100.43% 100.14% 100.05% 100.08%
Interest Burden Percent		 97.96% 97.79% 97.39% 93.11% 95.97% 95.97% 97.55% 101.40% 110.17% 109.93% 112.11%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -139.89% -134.17% -101.70% -117.71% -158.50% -238.87% -195.18% -177.70% -200.35% -96.08% -98.16%
ROIC Less NNEP Spread (ROIC-NNEP)		 -133.75% -127.68% -96.68% -112.18% -150.98% -230.08% -186.11% -167.24% -185.99% -62.39% -532.94%
Return on Net Nonoperating Assets (RNNOA)		 94.06% 89.69% 67.97% 74.25% 102.31% 164.53% 128.83% 114.65% 126.79% 19.80% -22.84%
Return on Equity (ROE)		 -45.83% -44.48% -33.73% -43.47% -56.19% -74.35% -66.34% -63.06% -73.57% -76.27% -121.00%
Cash Return on Invested Capital (CROIC)		 -167.91% -166.77% -131.53% -113.25% -127.78% -167.71% -161.74% -167.17% -215.13% -234.81% -216.47%
Operating Return on Assets (OROA)		 -37.35% -33.73% -28.07% -33.75% -46.22% -55.39% -55.91% -36.20% -41.15% -36.72% -46.17%
Return on Assets (ROA)		 -36.68% -33.11% -27.34% -31.42% -44.35% -53.16% -54.70% -36.86% -45.40% -40.39% -51.81%
Return on Common Equity (ROCE)		 -45.83% -44.48% -33.73% -43.47% -56.19% -74.35% -66.34% -63.06% -73.57% -76.27% -121.00%
Return on Equity Simple (ROE_SIMPLE)		 -90.71% 0.00% -59.64% -55.96% -62.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.43 -3.29 -2.96 -3.32 -3.62 -3.92 -4.31 -3.98 -3.69 -4.93 -5.93
NOPAT Margin		 -59.49% -48.37% -38.77% -42.22% -44.58% -50.48% -50.84% -43.15% -41.68% -47.37% -48.93%
Net Nonoperating Expense Percent (NNEP)		 -6.14% -6.50% -5.02% -5.54% -7.52% -8.79% -9.06% -10.47% -14.37% -33.68% 434.78%
Return On Investment Capital (ROIC_SIMPLE)		 - -10.58% - - - -15.45% -21.58% -8.18% -8.19% -6.40% -8.67%
Cost of Revenue to Revenue		 43.20% 41.07% 40.76% 36.52% 40.32% 38.72% 39.52% 39.71% 36.80% 38.48% 36.05%
SG&A Expenses to Revenue		 50.33% 39.94% 37.19% 35.29% 38.85% 41.55% 48.11% 36.77% 40.47% 52.28% 41.20%
R&D to Revenue		 42.16% 38.94% 34.36% 39.70% 40.82% 42.88% 39.82% 41.55% 38.96% 31.10% 37.29%
Operating Expenses to Revenue		 141.79% 128.03% 114.62% 123.78% 123.36% 133.39% 133.12% 121.93% 122.74% 129.19% 133.86%
Earnings before Interest and Taxes (EBIT)		 -4.90 -4.71 -4.26 -4.73 -5.18 -5.61 -6.16 -5.73 -5.34 -7.08 -8.51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.46 -4.27 -3.77 -4.26 -4.67 -5.14 -5.83 -5.09 -4.88 -6.21 -7.36
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.12 7.90 5.30 4.60 10.67 16.71 16.44 16.93 39.02 13.88 14.33
Price to Tangible Book Value (P/TBV)		 5.34 8.30 5.44 4.71 10.90 17.03 16.82 16.93 39.02 58.68 0.00
Price to Revenue (P/Rev)		 5.53 6.98 7.01 5.27 10.17 13.52 10.19 9.95 18.04 10.52 6.65
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 11.25 19.29 17.19 13.48 38.74 76.47 41.60 45.62 89.03 12.57 8.63
Enterprise Value to Revenue (EV/Rev)		 4.88 6.43 6.04 4.45 9.46 12.88 9.81 9.57 17.78 10.60 6.99
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.41 0.47 0.29 0.31 0.00 0.00 0.00 1.46 1.84 1.75 2.63
Long-Term Debt to Equity		 0.41 0.47 0.00 0.00 0.00 0.00 0.00 1.46 1.84 1.75 2.63
Financial Leverage		 -0.70 -0.70 -0.70 -0.66 -0.68 -0.72 -0.69 -0.69 -0.68 -0.32 0.04
Leverage Ratio		 1.59 1.69 1.55 1.68 1.58 1.76 1.53 2.23 2.24 2.56 3.18
Compound Leverage Factor		 1.56 1.65 1.51 1.57 1.52 1.69 1.50 2.26 2.47 2.82 3.57
Debt to Total Capital		 29.20% 31.97% 22.37% 23.70% 0.00% 0.00% 0.00% 59.37% 64.78% 63.66% 72.49%
Short-Term Debt to Total Capital		 0.00% 0.00% 22.37% 23.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 29.20% 31.97% 0.00% 0.00% 0.00% 0.00% 0.00% 59.37% 64.78% 63.66% 72.49%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 70.80% 68.03% 77.63% 76.30% 100.00% 100.00% 100.00% 40.63% 35.22% 36.34% 27.51%
Debt to EBITDA		 -0.47 -0.47 -0.52 -0.60 0.00 0.00 0.00 -1.39 -1.39 -2.23 -2.11
Net Debt to EBITDA		 0.68 0.63 1.31 1.36 0.00 0.00 0.00 0.61 0.43 -0.14 -0.60
Long-Term Debt to EBITDA		 -0.47 -0.47 0.00 0.00 0.00 0.00 0.00 -1.39 -1.39 -2.23 -2.11
Debt to NOPAT		 -0.64 -0.63 -0.68 -0.77 0.00 0.00 0.00 -1.82 -1.83 -2.90 -2.68
Net Debt to NOPAT		 0.93 0.84 1.73 1.76 0.00 0.00 0.00 0.80 0.57 -0.19 -0.76
Long-Term Debt to NOPAT		 -0.64 -0.63 0.00 0.00 0.00 0.00 0.00 -1.82 -1.83 -2.90 -2.68
Altman Z-Score		 -0.60 0.01 2.12 0.44 11.24 12.64 11.45 1.25 4.64 1.03 -0.50
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.68 4.87 3.14 2.79 4.54 3.22 3.53 7.30 6.37 5.91 5.79
Quick Ratio		 4.79 3.55 2.50 2.18 3.37 2.40 2.34 6.19 5.24 4.87 4.67
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.82 -1.99 -1.40 -1.72 -1.36 -1.23 -2.72 -1.76 -3.12 -31 -31
Operating Cash Flow to CapEx		 -764.26% -5,566.67% 0.00% 0.00% -9,991.67% -472.62% -3,372.68% -2,804.40% -1,568.34% -24,653.06% -1,235.19%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -21.96 -5.75 -16.09 -22.60
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -31.90 -5.75 -6.30 -5.76
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -33.04 -6.11 -6.33 -6.23
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.44 0.49 0.50 0.56 0.72 0.77 0.77 0.58 0.68 0.54 0.66
Accounts Receivable Turnover		 7.65 8.15 10.08 8.95 9.66 7.92 10.46 8.69 8.72 6.57 6.60
Inventory Turnover		 1.08 1.20 1.26 1.31 1.50 1.66 1.72 1.86 1.95 1.88 2.02
Fixed Asset Turnover		 22.50 21.83 22.79 19.32 19.95 18.50 18.26 18.85 18.03 15.98 15.94
Accounts Payable Turnover		 8.60 31.10 10.22 10.76 13.83 14.16 12.14 11.30 15.83 11.00 8.63
Days Sales Outstanding (DSO)		 47.71 44.77 36.20 40.79 37.78 46.07 34.89 42.02 41.86 55.59 55.33
Days Inventory Outstanding (DIO)		 337.04 303.80 288.90 279.09 242.90 219.78 212.19 196.61 187.45 194.55 180.79
Days Payable Outstanding (DPO)		 42.46 11.74 35.71 33.93 26.40 25.78 30.06 32.30 23.06 33.18 42.30
Cash Conversion Cycle (CCC)		 342.28 336.83 289.40 285.96 254.28 240.07 217.02 206.33 206.25 216.97 193.82
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 9.69 7.98 9.20 9.27 7.43 5.29 7.60 7.05 6.86 31 33
Invested Capital Turnover		 2.35 2.77 2.62 2.79 3.56 4.73 3.84 4.12 4.81 2.03 2.01
Increase / (Decrease) in Invested Capital		 0.39 -1.31 -1.56 -1.60 -2.26 -2.70 -1.60 -2.22 -0.57 26 25
Enterprise Value (EV)		 109 154 158 125 288 404 316 321 610 392 284
Market Capitalization		 123 167 183 148 309 424 329 334 619 389 270
Book Value per Share		 $0.98 $0.86 $1.28 $1.17 $1.05 $0.92 $0.72 $0.71 $0.56 $0.99 $0.64
Tangible Book Value per Share		 $0.94 $0.82 $1.25 $1.14 $1.03 $0.90 $0.71 $0.71 $0.56 $0.23 ($0.07)
Total Capital		 34 31 45 42 29 25 20 49 45 77 68
Total Debt		 9.94 9.95 9.96 9.98 0.00 0.00 0.00 29 29 49 50
Total Long-Term Debt		 9.94 9.95 0.00 0.00 0.00 0.00 0.00 29 29 49 50
Net Debt		 -14 -13 -25 -23 -22 -20 -12 -13 -9.02 3.15 14
Capital Expenditures (CapEx)		 0.24 0.02 0.00 0.00 0.01 0.26 0.18 0.09 0.20 0.05 0.65
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 7.38 5.60 7.02 7.00 5.20 2.91 4.96 5.05 5.06 6.91 9.80
Debt-free Net Working Capital (DFNWC)		 32 29 42 40 27 23 17 47 43 53 45
Net Working Capital (NWC)		 32 29 32 30 27 23 17 47 43 53 45
Net Nonoperating Expense (NNE)		 1.38 1.32 1.18 1.09 1.35 1.46 1.71 1.86 2.20 2.85 3.62
Net Nonoperating Obligations (NNO)		 -14 -13 -25 -23 -22 -20 -12 -13 -9.02 3.15 14
Total Depreciation and Amortization (D&A)		 0.44 0.44 0.49 0.48 0.52 0.47 0.33 0.65 0.47 0.87 1.16
Debt-free, Cash-free Net Working Capital to Revenue		 33.06% 23.39% 26.85% 24.92% 17.10% 9.26% 15.39% 15.04% 14.72% 18.70% 24.14%
Debt-free Net Working Capital to Revenue		 142.13% 119.98% 161.99% 141.94% 88.00% 73.30% 53.82% 138.70% 126.05% 142.91% 111.78%
Net Working Capital to Revenue		 142.13% 119.98% 123.90% 106.39% 88.00% 73.30% 53.82% 138.70% 126.05% 142.91% 111.78%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.20) ($0.18) ($0.16) ($0.16) ($0.18) ($0.20) ($0.22) ($0.21) ($0.21) ($0.26) ($0.32)
Adjusted Weighted Average Basic Shares Outstanding		 24.63M 24.61M 25.45M 27.47M 27.59M 27.03M 27.72M 28.26M 28.43M 28.32M 29.55M
Adjusted Diluted Earnings per Share		 ($0.20) ($0.18) ($0.16) ($0.16) ($0.18) ($0.20) ($0.22) ($0.21) ($0.21) ($0.26) ($0.32)
Adjusted Weighted Average Diluted Shares Outstanding		 24.63M 24.61M 25.45M 27.47M 27.59M 27.03M 27.72M 28.26M 28.43M 28.32M 29.55M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 24.62M 26.98M 27.42M 27.60M 27.58M 27.63M 27.99M 28.43M 28.42M 29.66M 29.99M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.43 -3.29 -2.96 -3.32 -3.62 -3.92 -4.31 -3.98 -3.69 -4.93 -5.93
Normalized NOPAT Margin		 -59.49% -48.37% -38.77% -42.22% -44.58% -50.48% -50.84% -43.15% -41.68% -47.37% -48.93%
Pre Tax Income Margin		 -83.25% -67.58% -54.27% -56.10% -61.24% -69.31% -70.81% -63.07% -66.39% -74.76% -78.69%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -71.65 -9.83 -3.69 -6.16
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -49.70 -6.80 -2.57 -4.29
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -72.79 -10.20 -3.72 -6.63
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -50.84 -7.17 -2.60 -4.76
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

ClearPoint Neuro (NASDAQ: CLPT) is still growing revenue, but losses remain wide and the company continues to burn cash. Over the last several years, the top line has trended higher, but operating expenses have risen alongside it, keeping the business unprofitable. The latest quarter also showed a meaningful decline in cash from the prior quarter, even though the balance sheet still has a sizeable cash position.

  • Revenue continues to trend upward: Q1 2026 revenue was $12.1 million, up from $10.4 million in Q4 2025 and $8.5 million in Q1 2025.
  • Gross profit improved in absolute dollars, reaching $7.8 million in Q1 2026 versus $6.4 million in Q4 2025.
  • The company ended Q1 2026 with $35.6 million in cash and equivalents, giving it a cushion to fund operations.
  • Total assets increased to $93.4 million in Q1 2026, up sharply from $60.4 million in Q3 2025, reflecting a larger asset base after recent financing activity and business growth.
  • CLPT has significantly reduced its debt burden versus a year ago: long-term debt was $49.6 million in Q1 2026, down from $29.2 million in Q3 2025 after debt and financing changes shifted over time.
  • The company’s share count has drifted higher over time, with weighted average basic shares at 29.5 million in Q1 2026 versus 27.7 million in Q1 2025, which can dilute per-share results.
  • The balance sheet still shows a meaningful amount of intangible assets, goodwill, and other noncurrent operating assets, which are common in acquisition-driven growth but can be less liquid than cash.
  • CLPT remains unprofitable: Q1 2026 net loss was $9.6 million, or -$0.32 per share.
  • Operating losses widened year over year in the latest quarter, with operating income at -$8.5 million in Q1 2026 versus -$6.2 million in Q1 2025.
  • Cash from operations was negative -$8.0 million in Q1 2026, showing the core business is still consuming cash rather than generating it.

Longer-term trend: Revenue has roughly doubled from the low-$5 million range in early 2023 to the low-$12 million range in early 2026, which is encouraging. However, operating expenses have also expanded, especially marketing and R&D, and the company has not yet translated growth into profitability. In fact, quarterly losses have generally stayed in the $4 million to $10 million range for the last several years.

Balance sheet takeaway: ClearPoint Neuro appears to have enough liquidity for now, but the negative operating cash flow means investors should keep an eye on how quickly cash is being consumed. The company’s ability to keep growing revenue faster than expenses will likely determine whether the stock can re-rate higher.

07/09/26 01:59 AM ETAI Generated. May Contain Errors.

ClearPoint Neuro Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ClearPoint Neuro's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

ClearPoint Neuro's net income appears to be on an upward trend, with a most recent value of -$25.54 million in 2025, rising from -$8.45 million in 2015. The previous period was -$18.91 million in 2024. View ClearPoint Neuro's forecast to see where analysts expect ClearPoint Neuro to go next.

ClearPoint Neuro's total operating income in 2025 was -$24.16 million, based on the following breakdown:
  • Total Gross Profit: $22.69 million
  • Total Operating Expenses: $46.86 million

Over the last 10 years, ClearPoint Neuro's total revenue changed from $4.59 million in 2015 to $36.97 million in 2025, a change of 704.7%.

ClearPoint Neuro's total liabilities were at $69.73 million at the end of 2025, a 405.3% increase from 2024, and a 485.1% increase since 2015.

In the past 10 years, ClearPoint Neuro's cash and equivalents has ranged from $3.10 million in 2018 to $54.11 million in 2021, and is currently $45.92 million as of their latest financial filing in 2025.

Over the last 10 years, ClearPoint Neuro's book value per share changed from -0.03 in 2015 to 0.99 in 2025, a change of -3,834.1%.


Related Companies

Financial statements for NASDAQ:CLPT last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel